Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320085 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT01320085 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 183 participants.
The verdict
NCT01320085, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
Interventions
- DRUG MEK162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2011-03-24 |
| Est. Completion | 2023-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01320085
The ClinicalTrials.gov registry entry for NCT01320085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEK162 is the first listed.
NCT01320085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01320085 about?
NCT01320085 is a clinical study titled "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma". The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
What is the current status of trial NCT01320085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2011-03-24. Estimated completion is 2023-02-06.
What interventions are being tested in trial NCT01320085?
The interventions under investigation include: MEK162 (DRUG).
Who is sponsoring clinical trial NCT01320085?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.